ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VTVT vTv Therapeutics Inc

23.63
-0.0699 (-0.29%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
vTv Therapeutics Inc NASDAQ:VTVT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0699 -0.29% 23.63 22.64 100.00 24.33 22.5001 22.85 9,458 05:00:09

vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

02/12/2019 12:30pm

GlobeNewswire Inc.


vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more vTv Therapeutics Charts.

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general company update at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 10:50 a.m. Eastern Time in New York City. Company management will also be meeting with members of the investment community during one-on-one meetings at the conference.

A live webcast of the presentation can be accessed here and will be accessible for 30 days following the presentation at www.vtvtherapeutics.com.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, COPD, and genetic mitochondrial diseases.

ContactsInvestors: vTv Therapeutics Inc. IR@vtvtherapeutics.com

or Media:Glenn SilverLazar FINN Partners646-871-8485gsilver@lazarpartners.com

1 Year vTv Therapeutics Chart

1 Year vTv Therapeutics Chart

1 Month vTv Therapeutics Chart

1 Month vTv Therapeutics Chart

Your Recent History

Delayed Upgrade Clock